Junctional epidermolysis bullosa

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:305
Who is this for?
Show terms as
1FDA treatments1Active trials27Specialists8Treatment centers1Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Junctional epidermolysis bullosa (JEB) is a rare and serious inherited skin condition where the skin and mucous membranes are extremely fragile. In healthy skin, different layers are held together by proteins that act like anchors. In JEB, mutations in the genes that make these anchoring proteins cause the layers to separate easily, leading to painful blisters and open wounds that form with very little friction or trauma — sometimes even from normal handling or clothing. JEB is one of the main types of epidermolysis bullosa (EB), a group of conditions sometimes called 'butterfly skin' because the skin is as fragile as a butterfly's wings. JEB affects not just the outer skin but also the moist linings inside the body, including the mouth, throat, esophagus, airways, eyes, and urinary tract. This means eating, swallowing, and breathing can all be affected. Blistering at birth or shortly after is common, and wounds can be slow to heal and prone to infection. Some forms of JEB are very severe and life-threatening in infancy, while others are milder and allow survival into adulthood. There is currently no cure for JEB, but treatment focuses on careful wound care, preventing infection, managing pain, and supporting nutrition. A gene therapy product called beremagene geperpavec (B-VEC, brand name Vyjuvek) has received FDA approval for a related form of EB, and research into gene and cell therapies for JEB is actively ongoing. A team of specialists is usually needed to manage this complex condition.

Also known as:

Key symptoms:

Blisters forming on the skin with little or no injuryOpen sores and wounds that are slow to healBlistering inside the mouth and throatDifficulty swallowing due to blisters in the esophagusHoarse voice or breathing problems from blisters in the airwayEye irritation, redness, or scarringNail loss or abnormal nail growthHair loss (in some subtypes)Dental problems including tooth decay and enamel defectsScarring of the skin over timeAnemia (low red blood cell count) from chronic woundsPoor growth and low body weight due to feeding difficultiesUrinary problems from blistering in the urinary tractIncreased risk of skin infection

Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗NORD ↗

FDA & Trial Timeline

2 events
Dec 2023Filsuvez: FDA approved

Treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older

FDAcompleted
Jun 2018Gentamicin for Junctional Epidermolysis Bullosa

University of Southern California — PHASE1, PHASE2

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

Filsuvez

BIRCH TRITERPENES· Chiesi USA, Inc.Orphan Drug

Treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older

Clinical Trials

1 recruitingView all trials with filters →

Specialists

Showing 25 of 27View all specialists →
BL
Bernadette Liemberger
Specialist
4 Junctional epidermolysis bullosa publications
SH
Stefan Hainzl
Specialist
4 Junctional epidermolysis bullosa publications
CH
Cristina Has
Specialist
5 Junctional epidermolysis bullosa publications
JB
Johannes Bischof
Specialist
4 Junctional epidermolysis bullosa publications
SS
Saliha Beyza Sayar
Specialist
2 Junctional epidermolysis bullosa publications
AN
Alexander Nyström
Specialist
3 Junctional epidermolysis bullosa publications
UK
Ulrich Koller
Specialist
4 Junctional epidermolysis bullosa publications
TK
Thomas Kocher
SAN DIEGO, CA
Specialist
4 Junctional epidermolysis bullosa publications
JH
Josefina Piñón Hofbauer
Specialist
4 Junctional epidermolysis bullosa publications
VW
Verena Wally
Specialist
4 Junctional epidermolysis bullosa publications
CG
Christina Guttmann-Gruber
Specialist
4 Junctional epidermolysis bullosa publications
DS
Dirk Strunk
Specialist
4 Junctional epidermolysis bullosa publications
AM
Alexandra DJ Mancini, MSc
GREENACRES, FL
Specialist
PI on 1 active trial
TS
Thomas J Sproule
Specialist
2 Junctional epidermolysis bullosa publications
RW
Robert Y Wilpan
Specialist
2 Junctional epidermolysis bullosa publications
BL
Benjamin E Low
SAN FRANCISCO, CA
Specialist
2 Junctional epidermolysis bullosa publications
JS
John P Sundberg
Specialist
2 Junctional epidermolysis bullosa publications
DR
Derry C Roopenian
Specialist
2 Junctional epidermolysis bullosa publications
PE
Philipp R Esser
Specialist
2 Junctional epidermolysis bullosa publications
AL
Anna Letko
Specialist
2 Junctional epidermolysis bullosa publications
TC
Toni Cathomen
Specialist
2 Junctional epidermolysis bullosa publications
JB
Johann Wolfgang Bauer
Specialist
2 Junctional epidermolysis bullosa publications
JR
Julia Reichelt
Specialist
2 Junctional epidermolysis bullosa publications
HB
Heide-Marie Binder
Specialist
2 Junctional epidermolysis bullosa publications
IP
Igor Petković
Specialist
2 Junctional epidermolysis bullosa publications

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

1 resources
Filsuvez(BIRCH TRITERPENES)Chiesi USA, Inc.

Travel Grants

No travel grants are currently matched to Junctional epidermolysis bullosa.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Junctional epidermolysis bullosaForum →

No community posts yet. Be the first to share your experience with Junctional epidermolysis bullosa.

Start the conversation →

Latest news about Junctional epidermolysis bullosa

No recent news articles for Junctional epidermolysis bullosa.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Which specific subtype of JEB does my child or I have, and what does that mean for the long-term outlook?,Which genes are affected, and should other family members be tested?,What wound care routine and dressings do you recommend, and can we get training from a wound care nurse?,Are there any clinical trials for gene therapy or other new treatments that we might qualify for?,How should we handle a skin infection or breathing emergency at home?,What specialists should be part of our care team, and how often should we see each one?,What support resources or patient organizations do you recommend for families living with JEB?

Common questions about Junctional epidermolysis bullosa

What is Junctional epidermolysis bullosa?

Junctional epidermolysis bullosa (JEB) is a rare and serious inherited skin condition where the skin and mucous membranes are extremely fragile. In healthy skin, different layers are held together by proteins that act like anchors. In JEB, mutations in the genes that make these anchoring proteins cause the layers to separate easily, leading to painful blisters and open wounds that form with very little friction or trauma — sometimes even from normal handling or clothing. JEB is one of the main types of epidermolysis bullosa (EB), a group of conditions sometimes called 'butterfly skin' because

How is Junctional epidermolysis bullosa inherited?

Junctional epidermolysis bullosa follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Junctional epidermolysis bullosa typically begin?

Typical onset of Junctional epidermolysis bullosa is neonatal. Age of onset can vary across affected individuals.

Are there clinical trials for Junctional epidermolysis bullosa?

Yes — 1 recruiting clinical trial is currently listed for Junctional epidermolysis bullosa on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Junctional epidermolysis bullosa?

25 specialists and care centers treating Junctional epidermolysis bullosa are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.